• Ipsen Pharmaceuticals-Supply Interruptions

    May 2013 Re: IMPORTANT SUPPLY INTERRUPTION INFORMATION Ipsen Biopharmaceuticals, Inc. (“Ipsen”) markets Increlex® (mecasermin [rDNA origin] injection), NDC-15054-1040-5, as a 10 mg per mL sterile solution in multiple dose vials (40 mg per vial). Due to operational problems at our third-party manufacturer, Ipsen has been forced to limit purchases of Increlex. The remaining product supply… Read more »